Related Experiment Videos
Editorial: Antibody diversity: is it all coded for by the germ line genes?
Scandinavian Journal of Immunology
|January 1, 1974
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The cross-reactive idiotype of A-strain mice Serological and structural analyses.
Immunology today·2014
One from column A, one from column B.
Immunology today·2014
The coding properties of methyl-deficient leucyl-transfer RNA.
Journal of molecular biology·2009
CD45RO: a marker for BCR-mediated selection.
Scandinavian journal of immunology·2007
Evolution and Mechanistic Insights of Immunometabolism in Metabolic Diseases and Infections.
Scandinavian journal of immunology·2026
From Validation to Clinical Interpretation: A Flow Cytometric Th17-Cell Assay for STAT1- and STAT3-Related Inborn Errors of Immunity.
Scandinavian journal of immunology·2026
Impact of CD38 Deficiency on B Cell Development in CD19-Deficient Mice.
Scandinavian journal of immunology·2026
Decreased PD-1+ NK and T Cell Populations in Peritoneal Fluid contribute to Immune Dysregulation in Endometriosis.
Scandinavian journal of immunology·2026
Impact of Bacterial Membrane Vesicles on Cellular Responses in Leishmania amazonensis-Infected Macrophages In Vitro.
Scandinavian journal of immunology·2026
Therapeutic Potential of Group 2 Innate Lymphoid Cells in Neuroinflammatory Diseases.
Scandinavian journal of immunology·2026
Lung biopsy strategies for childhood interstitial lung disease: Indications and techniques.
The Journal of international medical research·2026
"I know how important it is": A qualitative analysis of participants' experiences in a vaccine safety study.
Human vaccines & immunotherapeutics·2026
Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.
Rheumatology (Oxford, England)·2026
Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.
Cancer chemotherapy and pharmacology·2026